Brasada Capital Management LP Grows Position in Emergent Biosolutions Inc (EBS)

Brasada Capital Management LP boosted its position in shares of Emergent Biosolutions Inc (NYSE:EBS) by 20.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,000 shares of the biopharmaceutical company’s stock after purchasing an additional 1,000 shares during the period. Brasada Capital Management LP’s holdings in Emergent Biosolutions were worth $395,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in Emergent Biosolutions by 20.2% during the second quarter. BlackRock Inc. now owns 5,372,711 shares of the biopharmaceutical company’s stock valued at $271,268,000 after purchasing an additional 901,882 shares during the last quarter. Renaissance Technologies LLC boosted its position in Emergent Biosolutions by 10.6% during the second quarter. Renaissance Technologies LLC now owns 2,066,511 shares of the biopharmaceutical company’s stock valued at $104,338,000 after purchasing an additional 198,600 shares during the last quarter. Northern Trust Corp boosted its position in Emergent Biosolutions by 11.3% during the second quarter. Northern Trust Corp now owns 1,150,184 shares of the biopharmaceutical company’s stock valued at $58,072,000 after purchasing an additional 117,098 shares during the last quarter. Rice Hall James & Associates LLC boosted its position in Emergent Biosolutions by 18.1% during the second quarter. Rice Hall James & Associates LLC now owns 1,141,021 shares of the biopharmaceutical company’s stock valued at $57,610,000 after purchasing an additional 174,614 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Emergent Biosolutions by 2.3% during the second quarter. Bank of New York Mellon Corp now owns 755,948 shares of the biopharmaceutical company’s stock valued at $38,167,000 after purchasing an additional 16,801 shares during the last quarter. 80.76% of the stock is owned by hedge funds and other institutional investors.

In related news, EVP Adam Havey sold 22,996 shares of the business’s stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $61.06, for a total transaction of $1,404,135.76. Following the completion of the transaction, the executive vice president now owns 36,079 shares of the company’s stock, valued at approximately $2,202,983.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Daniel Abdun-Nabi sold 90,776 shares of the business’s stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $60.18, for a total value of $5,462,899.68. Following the transaction, the chief executive officer now directly owns 257,343 shares of the company’s stock, valued at approximately $15,486,901.74. The disclosure for this sale can be found here. Insiders sold 163,625 shares of company stock valued at $10,082,146 in the last ninety days. Insiders own 13.40% of the company’s stock.

Shares of NYSE:EBS opened at $68.44 on Friday. Emergent Biosolutions Inc has a fifty-two week low of $37.06 and a fifty-two week high of $71.01. The stock has a market capitalization of $3.35 billion, a price-to-earnings ratio of 36.02, a P/E/G ratio of 1.49 and a beta of 1.27. The company has a quick ratio of 4.29, a current ratio of 5.52 and a debt-to-equity ratio of 0.01.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.07). Emergent Biosolutions had a return on equity of 12.89% and a net margin of 14.19%. The company had revenue of $173.70 million during the quarter, compared to analyst estimates of $185.16 million. During the same period in the prior year, the firm earned $0.73 EPS. Emergent Biosolutions’s quarterly revenue was up 16.3% on a year-over-year basis. As a group, analysts predict that Emergent Biosolutions Inc will post 2.2 EPS for the current fiscal year.

A number of research firms recently issued reports on EBS. Zacks Investment Research reissued a “hold” rating on shares of Emergent Biosolutions in a research report on Tuesday. Argus set a $80.00 price objective on Emergent Biosolutions and gave the company a “buy” rating in a research report on Friday, November 9th. Cantor Fitzgerald lifted their price objective on Emergent Biosolutions from $68.00 to $75.00 and gave the company an “overweight” rating in a research report on Friday, November 2nd. Goldman Sachs Group raised Emergent Biosolutions from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $60.00 to $75.00 in a research report on Friday, November 2nd. Finally, Chardan Capital boosted their price target on Emergent Biosolutions from $60.00 to $66.00 and gave the stock a “buy” rating in a research report on Tuesday, September 4th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Emergent Biosolutions presently has an average rating of “Buy” and a consensus target price of $66.25.

ILLEGAL ACTIVITY WARNING: “Brasada Capital Management LP Grows Position in Emergent Biosolutions Inc (EBS)” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/11/16/brasada-capital-management-lp-grows-position-in-emergent-biosolutions-inc-ebs.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Featured Story: Balanced Fund

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply